ALLR NASDAQ
Credit Risk of going bust: higher than 91% of companies Debt: 60.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.21 (down 77%), Allarity Therapeutics, Inc. would be worth roughly what it owes.
Total debt $22.3M against a stock market value of $14.6M.
Distance to default 1.42 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $22.3M (short-term plus half of long-term), stock volatility 76.6%; Altman Z'' -15.37. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Tarpon Springs, FL 34689
US
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Graff Jeremy R. | M-Exempt | 39,494 | — | 2026-09-30 |
| Graff Jeremy R. | F-InKind | 14,613 | $0.97 | 2026-09-30 |
| Graff Jeremy R. | M-Exempt | 39,494 | — | 2026-09-30 |
| Jensen Thomas | A-Award | 200,000 | — | 2026-01-28 |
| McLaughlin Gerald W. | A-Award | 45,000 | — | 2026-01-28 |